188 related articles for article (PubMed ID: 16753228)
1. HIV co-receptor inhibitors as novel class of anti-HIV drugs.
Schols D
Antiviral Res; 2006 Sep; 71(2-3):216-26. PubMed ID: 16753228
[TBL] [Abstract][Full Text] [Related]
2. Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists.
Lin G; Bertolotti-Ciarlet A; Haggarty B; Romano J; Nolan KM; Leslie GJ; Jordan AP; Huang CC; Kwong PD; Doms RW; Hoxie JA
J Virol; 2007 Sep; 81(18):9956-66. PubMed ID: 17609282
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs.
Seibert C; Sakmar TP
Curr Pharm Des; 2004; 10(17):2041-62. PubMed ID: 15279544
[TBL] [Abstract][Full Text] [Related]
4. Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs.
Nakata H; Steinberg SM; Koh Y; Maeda K; Takaoka Y; Tamamura H; Fujii N; Mitsuya H
Antimicrob Agents Chemother; 2008 Jun; 52(6):2111-9. PubMed ID: 18378711
[TBL] [Abstract][Full Text] [Related]
5. A novel assay to identify entry inhibitors that block binding of HIV-1 gp120 to CCR5.
Zhao Q; He Y; Alespeiti G; Debnath AK
Virology; 2004 Sep; 326(2):299-309. PubMed ID: 15321703
[TBL] [Abstract][Full Text] [Related]
6. CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy.
Grande F; Occhiuzzi MA; Rizzuti B; Ioele G; De Luca M; Tucci P; Svicher V; Aquaro S; Garofalo A
Molecules; 2019 Feb; 24(3):. PubMed ID: 30717348
[TBL] [Abstract][Full Text] [Related]
7. HIV co-receptors as targets for antiviral therapy.
Schols D
Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of R5X4 dualtropic HIV-1 primary isolates by single chemokine co-receptor ligands.
Ghezzi S; Menzo S; Brambilla A; Bordignon PP; Lorini AL; Clementi M; Poli G; Vicenzi E
Virology; 2001 Feb; 280(2):253-61. PubMed ID: 11162839
[TBL] [Abstract][Full Text] [Related]
9. [HIV entry into the cells--mechanisms and therapeutic possibilities].
Briz V; Poveda E; Soriano V
Med Clin (Barc); 2006 Mar; 126(9):341-8. PubMed ID: 16650368
[TBL] [Abstract][Full Text] [Related]
10. HIV entry inhibitors: progress in development and application.
Lai WH; Huang L; Chen CH
Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
[TBL] [Abstract][Full Text] [Related]
11. Progress in targeting HIV-1 entry.
Ryser HJ; Flückiger R
Drug Discov Today; 2005 Aug; 10(16):1085-94. PubMed ID: 16182193
[TBL] [Abstract][Full Text] [Related]
12. [Replication inhibitors targeting early events in the HIV-1 life cycle].
Ichiyama K; Yamamoto N
Nihon Rinsho; 2002 Apr; 60(4):784-9. PubMed ID: 11968789
[TBL] [Abstract][Full Text] [Related]
13. Development of anti-HIV agents targeting dynamic supramolecular mechanism: entry and fusion inhibitors based on CXCR4/CCR5 antagonists and gp41-C34-remodeling peptides.
Tamamura H; Otaka A; Fujii N
Curr HIV Res; 2005 Oct; 3(4):289-301. PubMed ID: 16250877
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
Reeves JD; Gallo SA; Ahmad N; Miamidian JL; Harvey PE; Sharron M; Pohlmann S; Sfakianos JN; Derdeyn CA; Blumenthal R; Hunter E; Doms RW
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16249-54. PubMed ID: 12444251
[TBL] [Abstract][Full Text] [Related]
15. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.
Donzella GA; Schols D; Lin SW; Esté JA; Nagashima KA; Maddon PJ; Allaway GP; Sakmar TP; Henson G; De Clercq E; Moore JP
Nat Med; 1998 Jan; 4(1):72-7. PubMed ID: 9427609
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor.
Derdeyn CA; Decker JM; Sfakianos JN; Zhang Z; O'Brien WA; Ratner L; Shaw GM; Hunter E
J Virol; 2001 Sep; 75(18):8605-14. PubMed ID: 11507206
[TBL] [Abstract][Full Text] [Related]
17. Co-receptor antagonists as HIV-1 entry inhibitors.
Shaheen F; Collman RG
Curr Opin Infect Dis; 2004 Feb; 17(1):7-16. PubMed ID: 15090884
[TBL] [Abstract][Full Text] [Related]
18. Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4.
Kazmierski WM; Kenakin TP; Gudmundsson KS
Chem Biol Drug Des; 2006 Jan; 67(1):13-26. PubMed ID: 16492145
[TBL] [Abstract][Full Text] [Related]
19. Chemokine receptor-directed agents as novel anti-HIV-1 therapies.
Mills SG; DeMartino JA
Curr Top Med Chem; 2004; 4(10):1017-33. PubMed ID: 15193136
[TBL] [Abstract][Full Text] [Related]
20. A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1.
Spenlehauer C; Gordon CA; Trkola A; Moore JP
Virology; 2001 Feb; 280(2):292-300. PubMed ID: 11162843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
